Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, DEC. 18, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED POSITIVE PRELIMINARY DATA FROM ITS ONGOING PHASE 1 CLINICAL STUDIES EVALUATING MICVOTABART PELIDOTIN (MICVO), A FIRST-IN-CONCEPT ANTIBODY-DRUG CONJUGATE (ADC) TARGETING EXTRADOMAIN-B OF FIBRONECTIN (EDB+FN), A NON-CELLULAR STRUCTURAL COMPONENT OF THE TUMOR EXTRACELLULAR MATRIX (ECM), IN PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC). THE UPDATE INCLUDES PRELIMINARY DATA FROM BOTH THE PHASE 1 MONOTHERAPY STUDY IN 2L+ R/M HNSCC AND THE PHASE 1/2 STUDY EVALUATING MICVO IN COMBINATION WITH MERCK'S (KNOWN AS MSD OUTSIDE OF THE US AND CANADA) ANTI-PD-1 THERAPY, PEMBROLIZUMAB, IN 1L/2L+ R/M HNSCC.

PYXIS ONCOLOGY ANNOUNCES POSITIVE PRELIMINARY PHASE 1 DATA FOR MICVOTABART PELIDOTIN (MICVO) IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN NOVEMBER 2025:

PYXIS ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

- PRELIMINARY DATA FROM ONGOING PHASE 1 CLINICAL STUDIES OF MICVOTABART PELIDOTIN (MICVO) IN PATIENTS WITH RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) EXPECTED IN THE FOURTH QUARTER OF 2025 - CLINICAL UPDATE TO FOCUS ON PRELIMINARY DATA FROM PHASE 1 MONOTHERAPY DOSE EXPANSION STUDY OF MICVO IN 2L/3L R/M HNSCC PATIENTS, INCLUDING FROM BOTH POST PLATINUM & PD-1 AND POST EGFR & PD-1 ARMS, AND PRELIMINARY DATA FROM PHASE 1/2 COMBINATION DOSE ESCALATION STUDY OF MICVO AND KEYTRUDA (PEMBROLIZUMAB) IN 1L/2L+ R/M HNSCC PATIENTS - PRESENTED TRANSLATIONAL DATA AT ESMO 2025 AND AACR-NCI-EORTC PROVIDING MEANINGFUL INSIGHTS INTO MICVO'S FIRST-IN-CONCEPT NON-CELLULAR TARGETING ANTIBODY DRUG CONJUGATE (ADC) MECHANISM OF ACTION - EXPECTED CASH RUNWAY THROUGH DATA MILESTONES AND INTO THE SECOND HALF OF 2026 BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- PYXIS ONCOLOGY, INC. (NASDAQ: PYXS), A CLINICAL-STAGE COMPANY DEVELOPING NEXT-GENERATION THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS, TODAY PROVIDED A BUSINESS UPDATE, AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025. IN THE DYNAMIC LANDSCAPE OF EMERGING CLINICAL-STAGE THERAPIES FOR PATIENTS WITH RECURRENT AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, A SIGNIFICANT UNMET MEDICAL NEED REMAINS DESPITE THE POTENTIAL IMPROVEMENTS IN TREATMENT OPTIONS, SAID LARA S.

Pyxis Oncology, Inc.

PYXS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Pyxis Oncology, Inc.

PYXS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PYXS